Challenges and Opportunity With MRI

EP: 1.The Value of Biomarker in Multiple Sclerosis

EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis

EP: 3.Assays to Detect Neurofilament Light

Now Viewing

EP: 4.Challenges and Opportunity With MRI

EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions

EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care

EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI

EP: 8.How to Address Increasing Neurofilament Light Chain Levels

EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels

EP: 10.Monitoring Patients After a Change in Treatment Regimen

EP: 11.Assessing Lesion Types With MS Biomarkers

EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease

EP: 13.The CLIMB Study

EP: 14.Reimbursement for MRI

EP: 15.Understanding the Underlying Progression of Multiple Sclerosis

EP: 16.Biomarkers, Patient Communication, and the Future of Care

EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers

Mark Freedman, MD, MSc, questions Ahmed Obeidat, MD, PhD, on his satisfaction with MRI as the primary biomarker for multiple sclerosis (MS) and how variability, cost, and limitations in conventional MRI impact clinical monitoring. Ahmed Obeidat, MD, PhD, acknowledges the challenges and highlights the reduced frequency of ordering MRIs, especially for stable patients on highly effective therapies.

Expressing dissatisfaction with the limited utility of conventional MRI for monitoring, Ahmed Obeidat, MD, PhD, emphasizes the importance of advanced MRI techniques, mentioning volume metrics, central vein sign, and normally appearing white matter. He discusses the need for quantitative biomarkers, expressing interest in fluid biomarkers for their potential in providing additional information beyond conventional MRIs.

Ahmed Obeidat, MD, PhD, advocates for combining imaging and fluid biomarkers in clinical practice for a more comprehensive understanding of the disease. He underscores the value of a quantitative biomarker, stating it could enhance patient comprehension and aid in assessing disease control.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.